GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » DOD Biotech PCL (BKK:DOD-F) » Definitions » EBIT

DOD Biotech PCL (BKK:DOD-F) EBIT : ฿78.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is DOD Biotech PCL EBIT?

DOD Biotech PCL's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ฿7.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ฿78.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. DOD Biotech PCL's annualized ROC % for the quarter that ended in Mar. 2024 was -0.71%. DOD Biotech PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 3.03%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. DOD Biotech PCL's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 6.72%.


DOD Biotech PCL EBIT Historical Data

The historical data trend for DOD Biotech PCL's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DOD Biotech PCL EBIT Chart

DOD Biotech PCL Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 87.79 331.50 271.78 -417.13 57.15

DOD Biotech PCL Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.56 23.14 28.17 18.77 7.90

Competitive Comparison of DOD Biotech PCL's EBIT

For the Packaged Foods subindustry, DOD Biotech PCL's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DOD Biotech PCL's EV-to-EBIT Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, DOD Biotech PCL's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where DOD Biotech PCL's EV-to-EBIT falls into.



DOD Biotech PCL EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿78.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DOD Biotech PCL  (BKK:DOD-F) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

DOD Biotech PCL's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-39.448 * ( 1 - 77.71% )/( (1252.036 + 1227.108)/ 2 )
=-8.7929592/1239.572
=-0.71 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1457.639 - 137.614 - ( 67.989 - max(0, 282.798 - 371.956+67.989))
=1252.036

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1415.233 - 121.344 - ( 66.781 - max(0, 254.525 - 350.519+66.781))
=1227.108

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

DOD Biotech PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=31.604/( ( (915.832 + max(136.574, 0)) + (899.211 + max(131.882, 0)) )/ 2 )
=31.604/( ( 1052.406 + 1031.093 )/ 2 )
=31.604/1041.7495
=3.03 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(111.643 + 150.403 + 41.921) - (137.614 + 0.079 + 29.7)
=136.574

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(100.406 + 144.758 + 38.574) - (121.344 + 0 + 30.512)
=131.882

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

DOD Biotech PCL's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=77.987/1160.453
=6.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DOD Biotech PCL EBIT Related Terms

Thank you for viewing the detailed overview of DOD Biotech PCL's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


DOD Biotech PCL (BKK:DOD-F) Business Description

Traded in Other Exchanges
Address
No.111, Moo 2, Tumbol Taa jeen, Amphor Muengsamutsakhon, Samut Sakhon, THA, 74000
DOD Biotech PCL is engaged in the business of food supplements and health drinks of all kinds. The company offers Skincare products, Dietary supplements, Healthy supplements, and Own branded products. The majority of the company's revenue is derived from the supplementary business segment within Thailand. The segments of the group are Supplementary business, Manufacturing cosmetic and Network marketing, Manufacturing Extraction business, and others, of which a majority of revenue is derived from the Supplementary business segment.

DOD Biotech PCL (BKK:DOD-F) Headlines

No Headlines